Xlaire
2021-07-21
Finally
Novartis posts Q2 profit beat as sales pick up
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":176991255,"tweetId":"176991255","gmtCreate":1626851923177,"gmtModify":1631891642338,"author":{"id":3583883178492003,"idStr":"3583883178492003","authorId":3583883178492003,"authorIdStr":"3583883178492003","name":"Xlaire","avatar":"https://static.tigerbbs.com/f75e6b3f0e30fdc93e129907e599a3b1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Finally </p></body></html>","htmlText":"<html><head></head><body><p>Finally </p></body></html>","text":"Finally","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/176991255","repostId":2153619682,"repostType":4,"repost":{"id":"2153619682","kind":"news","pubTimestamp":1626844800,"share":"https://www.laohu8.com/m/news/2153619682?lang=&edition=full","pubTime":"2021-07-21 13:20","market":"us","language":"en","title":"Novartis posts Q2 profit beat as sales pick up","url":"https://stock-news.laohu8.com/highlight/detail?id=2153619682","media":"StreetInsider","summary":"ZURICH (Reuters) -Novartis boosted its second-quarter core net income by a fifth, beating market exp","content":"<p>ZURICH (Reuters) -Novartis boosted its second-quarter core net income by a fifth, beating market expectations, the Swiss drugmaker reported on Wednesday, as it kept its 2021 guidance.</p>\n<p>It generated net profit of $3.72 billion and increased core operating income 18% to $4.35 billion while sales in the three months through June rose 14% to $12.96 billion, a gain of 9% when stripping out currency fluctuations.</p>\n<p>Analysts polled by Refinitiv had on average expected net profit of $3.46 billion on revenue of $12.52 billion.</p>\n<p>Novartis said its key drug brands were performing well and its product development pipeline continued to progress.</p>\n<p>\"While demand is starting to return to pre-COVID-19 levels in most geographies and therapeutic areas, we still see a slight impact on parts of our business for example in oncology, generics and certain geographies,\" it said.</p>\n<p>\"We are assuming further easing of COVID-19 restrictions</p>\n<p>in the second half of the year with a positive impact on business dynamics.\"</p>\n<p>It reiterated it expected 2021 sales to grow at a low- to mid-single-digit percentage rate, with core operating income seen growing at a mid-single-digit percentage rate ahead of sales.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis posts Q2 profit beat as sales pick up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis posts Q2 profit beat as sales pick up\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 13:20 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=18700375><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) -Novartis boosted its second-quarter core net income by a fifth, beating market expectations, the Swiss drugmaker reported on Wednesday, as it kept its 2021 guidance.\nIt generated net...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18700375\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华","QTWO":"Q2 Holdings Inc"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18700375","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153619682","content_text":"ZURICH (Reuters) -Novartis boosted its second-quarter core net income by a fifth, beating market expectations, the Swiss drugmaker reported on Wednesday, as it kept its 2021 guidance.\nIt generated net profit of $3.72 billion and increased core operating income 18% to $4.35 billion while sales in the three months through June rose 14% to $12.96 billion, a gain of 9% when stripping out currency fluctuations.\nAnalysts polled by Refinitiv had on average expected net profit of $3.46 billion on revenue of $12.52 billion.\nNovartis said its key drug brands were performing well and its product development pipeline continued to progress.\n\"While demand is starting to return to pre-COVID-19 levels in most geographies and therapeutic areas, we still see a slight impact on parts of our business for example in oncology, generics and certain geographies,\" it said.\n\"We are assuming further easing of COVID-19 restrictions\nin the second half of the year with a positive impact on business dynamics.\"\nIt reiterated it expected 2021 sales to grow at a low- to mid-single-digit percentage rate, with core operating income seen growing at a mid-single-digit percentage rate ahead of sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":441,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/176991255"}
精彩评论